- Home
- TLSA vs MIST Comparison
TLSA vs MIST Comparison
Compare TLSA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | MIST |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.2M | 176.3M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TLSA | MIST |
|---|---|---|
| Price | $1.22 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 140.5K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,653.36 |
| Revenue Next Year | N/A | $12.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.63 |
| 52 Week High | $2.60 | $3.06 |
Technical Indicators
Market Signals| Indicator | TLSA | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 46.10 |
| Support Level | N/A | N/A |
| Resistance Level | $1.62 | $2.01 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 29.82 | 48.10 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).